DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
FARALIMOMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interferon alpha-1/13 binding agent
FARALIMOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDX-220
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MDX-220
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-811
1
Antibody
Investigational
Unknown
Unknown
Psoriasis
Interferon gamma inhibitor
AMG-811
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MNRP1685A
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MNRP1685A
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEPRANEMAB
1
Antibody
Investigational
Unknown
Unknown
Supranuclear Palsy, Progressive; Alzheimer Disease
Unknown
BEPRANEMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
9M1GV6L389
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATINUMAB
1
Antibody
Investigational
Unknown
Unknown
Spinal Cord Injuries
Reticulon-4 inhibitor
ATINUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
9UBQ62RW32
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMURUTAMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
Unknown
PIMURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5V1Y8T4RB6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GILORALIMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Head and Neck Neoplasms; Neoplasms; Pancreatic Neoplasms
Unknown
GILORALIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
W6C58X3BFH
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VORSETUZUMAB MAFODOTIN
1
Antibody
Investigational
Unknown
Unknown
Carcinoma, Renal Cell
CD70 antigen binding agent
VORSETUZUMAB MAFODOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
699619YVTQ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LMB-7
1
Antibody
Investigational
Unknown
Unknown
Central Nervous System Neoplasms
Lewis Y antigen binding agent
LMB-7
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAR-1349
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
SAR-1349
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KHK-2866
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Proheparin-binding EGF-like growth factor inhibitor
KHK-2866
×
Maximum Phase:
1
First Approval:
None
UNII:
111EN0IJ7C
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SOFITUZUMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Ovarian Neoplasms; Pancreatic Neoplasms
Mucin-16 binding agent
SOFITUZUMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
2X3CKG601L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MONO-DGA-RFB4
1
Antibody
Investigational
Unknown
Unknown
Lymphoma
CD22 binding agent
MONO-DGA-RFB4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PAVURUTAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PAVURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GEN-1053
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
GEN-1053
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PONSEGROMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
PONSEGROMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RM-1929
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RM-1929
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRALUZATAMAB
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PRALUZATAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FORAVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
FORAVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
377VY97V7S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-191
1
Antibody
Investigational
Unknown
Unknown
Severe Combined Immunodeficiency
Stem cell growth factor receptor inhibitor
AMG-191
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS161721
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BOS161721
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AD-439
1
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope polyprotein GP160 inhibitor
AD-439
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANTICTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Pancreatic Neoplasms
Frizzled-1 antagonist
VANTICTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
88WBI2D80S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLANVOTUMAB
1
Antibody
Investigational
Unknown
Unknown
Melanoma
5,6-dihydroxyindole-2-carboxylic acid oxidase other
FLANVOTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
ZNV4738BS6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOC31-PE
1
Antibody
Investigational
Unknown
Unknown
Carcinoma
Epithelial cell adhesion molecule binding agent
MOC31-PE
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RHIGM12B7
1
Antibody
Investigational
Unknown
Unknown
Melanoma
Programmed cell death 1 ligand 2 cross-linking agent
RHIGM12B7
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CYT-500 177LU
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms
Glutamate carboxypeptidase II binding agent
CYT-500 177LU
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-4212
1
Antibody
Investigational
Unknown
Unknown
Dermatitis, Atopic; Rhinitis, Allergic, Seasonal
Ig epsilon chain C region inhibitor
MEDI-4212
×
Maximum Phase:
1
First Approval:
None
UNII:
XK0D8BK5WY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDIUM IN 111 ALTUMOMAB PENTETATE
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
INDIUM IN 111 ALTUMOMAB PENTETATE
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CNTO-5825
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interleukin-13 inhibitor
CNTO-5825
×
Maximum Phase:
1
First Approval:
None
UNII:
JYB0ILB7HU
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HEFI-1
1
Antibody
Investigational
Unknown
Unknown
Lymphoma; Neoplasms
Tumor necrosis factor receptor superfamily member 8 binding agent
HEFI-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NARATUXIMAB EMTANSINE
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Leukocyte antigen CD37 binding agent
NARATUXIMAB EMTANSINE
×
Maximum Phase:
1
First Approval:
None
UNII:
WE1X5A83B9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MLN-2704
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Glutamate carboxypeptidase II binding agent
MLN-2704
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
6
7
8
9
10
11
12
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA